Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02960997 · ClinicalTrials.gov registry record · Phase 2
Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT02960997: Completed Phase 2 study, sponsored by Stanford University.
NCT02960997 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02960997, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
Epidermolysis bullosa (EB) simplex is a rare orphan disease caused by a mutation in DNA leading to abnormal dominant keratins in the skin. Patients with EB simplex develop lifelong painful thick soles on their feet, and current standard of care is supportive. This pilot study will target the dominant mutant keratin proteins in the skin to ameliorate the severity of EB simplex. The purpose is to improve the function of EB simplex feet with an application of topical sirolimus, 2%. The investigators plan on inhibiting the mTOR pathway to down regulate the translation of defective keratin proteins and work through anti proliferative pathways.
Interventions
- DRUG Vehicle
- DRUG Sirolimus, 2%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-05 |
| Est. Completion | 2021-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02960997
The ClinicalTrials.gov registry entry for NCT02960997 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT02960997 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02960997 about?
NCT02960997 is a clinical study titled "Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study". Epidermolysis bullosa (EB) simplex is a rare orphan disease caused by a mutation in DNA leading to abnormal dominant keratins in the skin. Patients with EB simplex develop lifelong painful thick soles on their feet, and current standard of care is supportive. This pilot study will target the dominan...
What is the current status of trial NCT02960997?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2016-05. Estimated completion is 2021-12-01.
What interventions are being tested in trial NCT02960997?
The interventions under investigation include: Vehicle (DRUG), Sirolimus, 2% (DRUG).
Who is sponsoring clinical trial NCT02960997?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.